表紙
市場調查報告書
商品編碼
974804

進行性上眼神經核麻痺症治療市場:各藥物類型,各流通管道,各地區:規模,佔有率,預測,機會分析,(2020年∼2027年)

Progressive Supranuclear Palsy Treatment Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日期: | 出版商: Coherent Market Insights | 英文 195 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

進行性上眼神經核麻痺症(PSP),和帕金森氏症同樣是神經退化性疾病。這個疾病,起因於腦的神經細胞損傷。這個疾病的一般症狀之一,是眼睛不能適當轉動。這個情況下,個人可能經驗視力障礙。這是影響身體的動作,步行的控制,也就是步行與平衡,表達,吞嚥,視覺,心情和行動,及思考的稀少腦功能障礙。

本報告提供進行性上眼神經核麻痺症治療市場相關調查,市場概要,以及各藥物類型,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各藥物類型
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 開發平台分析
  • 償付方案
  • 流行病學
  • PEST分析
  • 法規方案
  • 新產品的銷售
  • 合作與契約
  • 市場趨勢

第4章 全球進行性核上麻痺治療市場-冠狀病毒(COVID-19)大流行的影響

  • COVID-19市場方案
  • COVID-19對進行性上眼神經核麻痺症治療藥市場的影響

第5章 全球進行性上眼神經核麻痺症治療市場:各藥物類型,2016年∼2027年,(百萬美元)

  • 簡介
  • 多巴胺
  • 抗膽鹼促效劑
  • 三環抗憂鬱藥物
  • 其他

第6章 全球進行性上眼神經核麻痺症治療市場:各流通管道,2016年∼2027年,(百萬美元)

  • 簡介
  • 院內藥局
  • 零售藥局
  • 線上藥局

第7章 全球進行性上眼神經核麻痺症治療市場:各地區,2016年∼2027年,(百萬美元)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • AbbVie Inc.
    • Acorda Therapeutics Inc.
    • Biogen Inc.
    • Bristol-Myers Squibb Co.
    • Merck & Co. Inc.
    • UCB Biopharma
    • AlzProtect
    • Asceneuron Therapeutics
    • TauRx Pharmaceuticals
    • GlaxoSmithKline PLC
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Analyst Views

第9章 Section

目錄

Title:
Progressive Supranuclear Palsy Treatment Market, by Drug Type (Dopamine, Anticholinergic Agents, Tricyclic Antidepressants, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Progressive supranuclear palsy (PSP) is a neurodegenerative disease alike Parkinson's disease. The disease results from damage to nerve cells in the brain. One of the common symptomof the disease include inability to aim and move the eyes properly, where individuals may experience as blurring of vision. It is a rare brain disorder that affects body movement, control of walking i.e. gait and balance, speech, swallowing, vision, mood and behavior, and thinking.

Market Dynamics

Rising incidence of progressive supranuclear palsy (PSP) is expected to drive progressive supranuclear palsy treatment market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, reports that about 3-6 in every 100,000 people have progressive supranuclear palsy worldwide, and around 20,000 U.S. populace are suffering from progressive supranuclear palsy.

However, lack of identification or diagnosis of progressive supranuclear palsy are expected to hinder the market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, states that currently there are no specific laboratory tests or imaging approaches are definitively diagnose progressive supranuclear palsy.

Key features of the study:

  • This report provides in-depth analysis of the global progressive supranuclear palsy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global progressive supranuclear palsy treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global progressive supranuclear palsy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive supranuclear palsy treatment market.

Detailed Segmentation:

  • Global Progressive Supranuclear Palsy Treatment Market, By Drug Type:
    • Dopamine
    • Anticholinergic Agents
    • Tricyclic Antidepressants
    • Others
  • Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Progressive Supranuclear Palsy Treatment Market, By Region:
    • North America
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • AbbVie Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Acorda Therapeutics Inc.
    • Biogen Inc.
    • Bristol-Myers Squibb Co.
    • Merck & Co. Inc.
    • UCB Biopharma
    • AlzProtect
    • Asceneuron Therapeutics
    • TauRx Pharmaceuticals
    • GlaxoSmithKline PLC
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Progressive Supranuclear Palsy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Market Scenario
  • Impact of COVID-19 Market on the Progressive Supranuclear Palsy Treatment Products

5. Global Progressive Supranuclear Palsy Treatment Market, By Drug Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Dopamine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Anticholinergic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Tricyclic Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global Progressive Supranuclear Palsy Treatment Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Acorda Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol-Myers Squibb Co.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • UCB Biopharma
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AlzProtect
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Asceneuron Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • TauRx Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline PLC
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact